Eyeing RNAi potential in cancer and fibrosis, trans-Pacific biotech Sirnaomics lines up $47M Series C

endpts | April 29, 2019

With support from a syndicate that speaks to its extensive China ties, Gaithersburg, MD-based Sirnaomics has raised an additional $22 million to close out its C round. As its name suggests, the biotech is focused on all things related to small interfering RNA (siRNA), the key molecule mRNA silencing. Popularized by Alnylam, which scored the field’s first FDA approval, siRNA kicks off action in the RNA-induced silencing complex, which then goes on to cleave a specific mRNA, thereby downregulating target genes. Sirnaomics’ big idea is to employ a better vehicle to carry the siRNA cargo to cells: a polypeptide nano-particle, or PNP, composed of a branched histidine lysine polymer. According to the company, the peptide is biodegradable, offers protection to the siRNA while in the bloodstream, and can carry multiple siRNA sequences, allowing their products to go after multiple genes at once. The last property, it emphasizes, is especially crucial for targeting cancer.

Spotlight

This is a video on the topic Importance of Biotechnology in Agriculture,and I am trying to describe it properly with slideshow. Referring to the significant role of a transparent approach to the end user’s requirement of healthy products, farmers are required to assure producing the highest quality of the products.

Spotlight

This is a video on the topic Importance of Biotechnology in Agriculture,and I am trying to describe it properly with slideshow. Referring to the significant role of a transparent approach to the end user’s requirement of healthy products, farmers are required to assure producing the highest quality of the products.

Related News

INOVIO Reports FDA Partial Clinical Hold for Planned Phase 2 / 3 Trial of COVID-19 Vaccine Candidate INO-4800

INOVIO | September 28, 2020

INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, announced that the U.S. Food and Drug Administration (FDA) has notified the company it has additional questions about the company's planned Phase 2/3 trial of its COVID-19 vaccine candidate INO-4800, including its CELLECTRA® 2000 delivery device to be used in the trial. Until the FDA's questions have been satisfactorily addressed, INOVIO's Investigational New Drug Application (IND) for the Phase 2/3 trial is on partial clinical hold. The company is actively working to address the FDA's questions and plans to respond in October, after which the FDA will have up to 30 days to notify INOVIO of its decision as to whether the trial may proceed. This partial clinical hold is not due to the occurrence of any adverse events related to INOVIO's ongoing expanded Phase 1 study of INO-4800, the conduct of which may continue and is not impacted by the FDA's notification. In addition, this partial clinical hold does not impact the advancement of INOVIO's other product candidates in development. INOVIO and its partners are continuing to prepare for a planned Phase 2/3 trial of INO-4800, following resolution of the FDA's partial clinical hold and subject to the receipt of external funding to conduct the trial.

Read More

CELL AND GENE THERAPY

Moderna and Aldevron Announce Expanded Collaboration for mRNA Vaccine and Therapeutic Pipeline

Moderna, Aldevron | May 25, 2021

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Aldevron, LLC, the leading provider of high-quality plasmid DNA, mRNA, and recombinant proteins used for vaccines, gene and cell therapy, gene editing, and diagnostic applications, have announced an expanded collaboration in support of the Moderna COVID-19 Vaccine and additional programs in mRNA therapeutics and vaccines. Aldevron will specifically provide plasmid DNA to act as the genetic template for the COVID-19 mRNA vaccine and other investigational programs in Moderna's pipeline. “Aldevron has been a long-standing Moderna partner. We value their cooperation and expertise in the biologics space,” said Juan Andres, Moderna's Chief Technical Operations and Quality Officer. “We are looking to continue our work in this extended partnership.” “Aldevron's support for the Moderna pipeline spans nearly a decade, and we're incredibly proud of the trust they've got in us,” said Kevin Ballinger, Aldevron's Chief Executive Officer. “Our extensive experience, combined with improved operational efficiencies and recent capacity expansion, puts us in an excellent position to support Moderna's efforts – especially at this critical stage. We look forward to extending our strategic partnership in the future to serve a pipeline of important new programs.” Aldevron's DNA production continues in its 70,000 square foot GMP facility in Fargo, North Dakota. The design and validation of an additional 189,000 sq ft expansion to Aldevron's 14-acre Breakthrough Campus's GMP facility have been completed, allowing for increased production capability. About Aldevron Aldevron is a world-class manufacturing partner in the area of genetic medicine. Michael Chambers and John Ballantyne founded the company in 1998, and it offers essential nucleic acids and proteins used in gene and cell therapies, DNA and RNA vaccines, and gene editing technologies. Aldevron's 600 employees assist thousands of scientists who are working to develop revolutionary treatments for millions of people. About Moderna Moderna has evolved from a science research-stage company advancing programs in the field of messenger RNA (mRNA) to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas such as mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant. Moderna maintains partnerships with a wide range of domestic & global government and commercial collaborators, allowing for the pursuit of both groundbreaking science and accelerated manufacturing scaling. Recently, Moderna's capabilities came together to allow the authorized use of one of the earliest and most effective COVID-19 vaccines.

Read More

MEDICAL

AlgaEnergy Agreements with Laboratoire M2 for Distribution and Product Development

AlgaEnergy | January 14, 2021

AlgaEnergy N.A. Inc., the U.S. subsidiary of Spain-based AlgaEnergy S.A. furthermore, a worldwide pioneer in microalgae biotechnology, has marked worldwide item conveyance and item improvement concurrences with Laboratoire M2 Inc., a Quebec-based biotechnology organization that creates normal and practical disinfectant items, including THYMOX CONTROL® fungicide and bactericide. AlgaEnergy formulates and creates incredible, manageable, microalgae-based yield contributions for the world's producers. Laboratoire M2's THYMOX® items, gotten from the antimicrobial intensity of thyme oil and other regular oils, are utilized in harvest and indoor farming, just as in turf and nursery markets. Under the arrangements, AlgaEnergy will acquire restrictive worldwide rights to disperse the THYMOX crop insurance product offering through AlgaEnergy's specialty units in key rural business sectors in Europe, the Americas, Africa and Asia-Pacific. The two organizations likewise marked a permit and collective item advancement understanding under which their logical groups will together attempt to make new, value-added biocontrol products.

Read More